Takeda takes step towards EU Entyvio extension

1 April 2019

The European Medicines Agency (EMA) has accepted a Marketing Authorization Line Extension Application for subcutaneous (SC) Entyvio (vedolizumab) for maintenance therapy in moderately to severely active ulcerative colitis (UC) or Crohn’s disease (CD).

This additional treatment modality, on top of the existing intravenous (IV) formulation, would provide greater choice in how patients receive Takeda’s (TYO: 4502) gut-selective biologic.

Adam Zaeske, head of the gastrointestinal franchise for Takeda’s Europe and Canada Business Unit, said: “This regulatory application marks an important milestone in our continued commitment to delivering innovative medicines and treatment modalities that meet the diverse needs of patients living with ulcerative colitis and Crohn’s disease across Europe.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK